The U.S. Food and Drug Administration approved the first generic of Climara Pro on October 20, 2026, the agency announced. The approved product is an estradiol and levonorgestrel transdermal system delivering 0.045 mg estradiol per day and 0.015 mg levonorgestrel per day, designed for once-weekly application. The FDA stated the generic is therapeutically equivalent to the reference listed drug. The agency framed the approval within its public-health objectives of expanding access to affordable medicines.
The approval covers women with an intact uterus. The labeling, as described by the FDA, specifies two indications: treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. The patch combines estrogen and progestogen in one application; the source emphasized that the progestogen is included specifically to reduce the risk of endometrial hyperplasia that can occur with estrogen-only regimens. The release did not describe age ranges, comorbidity exclusions beyond the contraindications listed below, or detailed prescribing guidance beyond the labeled indications.
The FDA listed multiple contraindications for both Climara Pro and the generic estradiol and levonorgestrel transdermal system. Contraindications include undiagnosed abnormal genital bleeding; breast cancer or a history of breast cancer; estrogen-dependent neoplasia; active deep vein thrombosis (DVT), pulmonary embolism (PE) or a history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction, angioedema, or hypersensitivity to estradiol and levonorgestrel; hepatic impairment or disease; and deficiencies in protein C, protein S, antithrombin, or other thrombophilic disorders. Clinicians should consult full prescribing information for complete safety language.
The agency also reported the most common adverse reactions occurring at a frequency of greater than or equal to 5%. These included application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome. The FDA release did not present comparative adverse event rates versus the brand product; it limited its summary to the most frequent reactions identified in the labeling.
The approved generic matches the reference product in active components and dosing: estradiol 0.045 mg per day combined with levonorgestrel 0.015 mg per day in a once-weekly transdermal patch. The FDA explicitly stated therapeutic equivalence to Climara Pro. The source did not provide detailed pharmacokinetic data, bioequivalence study specifics, or manufacturing-process descriptions in the announcement. Readers seeking those data should review the Orange Book entry or the abbreviated new drug application documentation for full technical details.
Zydus Pharmaceuticals (USA) Inc. received the FDA approval for its Estradiol and Levonorgestrel Transdermal System, the agency noted. The release linked this action to FDA efforts to increase generic availability and competition in the marketplace, citing the agency’s Drug Competition Action Plan and the broader public-health pillar of increasing access to affordable medicines. The FDA observed that nine out of 10 U.S. prescriptions are for generics, underscoring the practice-wide role of generics in cost containment. The FDA advised contacting the manufacturer for information about product availability; the agency did not publish a launch date or pricing information.
The source did not provide several operational and clinical specifics that prescribers and formulary managers often seek. The announcement omitted any timelines for commercial launch, wholesale acquisition cost or expected list price, and did not comment on anticipated market share or substitution policies at state or insurer levels. The release did not summarize comparative efficacy or safety data versus Climara Pro beyond stating therapeutic equivalence, and no pharmacokinetic or bioequivalence study details were included in the public statement. The FDA also did not provide information about patient-assistance programs or distribution arrangements. For those details, the source directed readers to contact the manufacturer and to consult the Orange Book and FDA regulatory resources.
Limitations described in the announcement are limited to the scope of the approval statement itself; the FDA did not publish additional clinical-trial data or postmarketing surveillance plans in this press release. The absence of timing, pricing, and granular study data represents the primary unanswered questions documented in the source.
For media inquiries, the FDA provided contact numbers; consumer questions were directed to the FDA information line. Climara Pro remains a registered trademark of Bayer, and Zydus Pharmaceuticals (USA) Inc. is the approved manufacturer for the generic estradiol and levonorgestrel transdermal system; the source advised contacting the manufacturer for availability information.